Paul Romesser, MD
Gastrointestinal Cancers; Rectal Cancer; Anal Cancer; Pancreas Cancer; Liver Cancer; Breast Cancer; Image-guided radiation therapy (IGRT); Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Radiosurgery (SRS); Proton Beam Radiotherapy (PBRT)
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Romesser accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Boston University School of Medicine
Radiation Oncology - Memorial Sloan Kettering Cancer Center
I am a board-certified radiation oncologist who has expertise in using advanced techniques to treat cancer. These include image-guided radiation therapy, intensity-modulated radiation therapy, stereotactic radiosurgery, and proton beam radiotherapy. I am also actively involved in cancer clinical trials. I work to take ideas developed in the lab and translate them into actual trials and treatments that can benefit people with cancer. I am a member of the NRG Oncology colorectal and non-colorectal gastrointestinal cancer committees and the National Cancer Institute’s Rectal-Anal Task Force. My work has been published in Nature, Science, Lancet Oncology, Clinical Cancer Research, International Journal of Radiation Oncology and Biophysics, and Cancer.
At Memorial Sloan Kettering, we approach treating cancer as a team. I work closely with surgical and medical oncologists, radiologists, and pathologists. I can confidently tell my patients that they will receive the best care in the world because of the team of experts that will support them every step of the way. I make sure all my patients are aware of who is on their care team, our individual roles, and how we work together to create a personalized treatment plan.
I also make sure my patients have a solid understanding of their diagnosis. I take time to explain how radiation therapy fits into treating their disease, as well as all the potential benefits and side effects. While many patients have concerns about radiation therapy, I hope that after meeting with me, they and their families feel reassured about what lies ahead.
Clinical trials, in my opinion, offer patients an opportunity to get the most progressive cancer care available. I know that the decision to participate or not participate in a trial can make people anxious. Ultimately the decision is a very personal one for patients and their families. I hope that by explaining the ins and outs of clinical trials, I can help guide my patients to make the right decision for them.
After patients leave my office, I hope that they feel that they have a strong advocate who will stop at nothing to ensure they are getting the best treatment.
I can confidently tell my patients that they will receive the best care in the world because of the team of experts that will support them every step of the way.
- Clinical Trials Investigated by Dr. Romesser
- A Phase I Study of XRD-0394 in People with Cancer Who Are Receiving Palliative Radiation Therapy
- A Phase II Study Evaluating the Effectiveness of a Lower Dose of Chemoradiation to Treat Early-Stage Anal Cancer
- Clinical Trials Co-Investigated by Dr. Romesser
- A Phase II Study of Proton versus Photon Beam Radiotherapy to Treat Head and Neck Cancer
- A Study Assessing the Effects of Chemotherapy or Radiation Therapy on Reproductive and Sexual Health in People with Early-Onset Colorectal Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, Sine KM, Tang S, Sherman EJ, Wong R, Lee NY. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiotherapy and Oncology. 2016; 118(2):286-292. PMID 26867969.
Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, Fox, JL, Mah D, Garg, MK, Chang J, Lee NY. Proton beam re-irradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. International Journal of Radiation Oncology Biology, and Physics. 2016; 95(1):386-395. PMID: 27084656.
Romesser PB, Romanyshyn JC, Schupak KD, Setton J, Riaz N, Wolden SL, Gelblum DY, Sherman EJ, Kraus D, Lee NY. Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy. Cancer. 2012; 118(24):6072-6078. PMID 22707358.
Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM, Lee NY. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. Journal of Surgical Oncology. 2014; 110(4):375-382. PMID 24961938.
Romesser PB, Lim R, Spratt DE, Setton J, Riaz N, Lok B, Sherman EJ, Schoder H, Lee NY. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pretreatment 18F-fluorodeoxyglucose positron emission tomography scan. Oral Oncology. 2014; 50(9):802-808. PMID 25043882.
Visit PubMed for a full listing of Dr. Romesser’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Paul Romesser discloses the following relationships and financial interests:
Healthcare Advisors Bureau
Provision of Services
High Sierra Area Health Education Center
Provision of Services
Ownership / Equity Interests
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.